Number of prostate cancer risk alleles may identify possibly 'insignificant' disease

BJU Int. 2010 Dec;106(11):1602-6. doi: 10.1111/j.1464-410X.2010.09440.x.


Objective: To determine whether the cumulative effects of five prostate cancer risk alleles (three single-nucleotide polymorphisms [SNPs] on chromosome 8Q24 and two SNPs on chromosome 17a) could help to identify possibly 'insignificant' disease.

Materials and methods: We genotyped 629 men of European ancestry who underwent radical prostatectomy at our institution between 2002 and 2007. Possibly 'insignificant' CaP was defined using the Ohori criteria (organ-confined, tumour volume <0.5 mL, Gleason pattern ≤4). Statistical analysis was used to compare patients with 'insignificant' and all other 'significant' cancer based upon genotype. Carrier status for the 5 SNPs were compared between patients with 'insignificant' disease and a separate population of 801 controls without CaP.

Results: Overall, 38 (6.0%) patients with CaP met the Ohori criteria for 'insignificant' disease. Men with 'significant' cancer had a greater frequency of any of the five risk alleles than either patients with 'insignificant' disease or controls. None of the individual alleles genotyped on chromosomes 8 or 17 distinguished between 'significant' and 'insignificant' CaP. However, carriers of two or more risk alleles were more likely to have 'significant' disease.

Conclusions: Although no single risk allele distinguished 'insignificant' CaP, 'insignificant' disease was nearly three times as likely among carriers of ≤ one risk allele. Future studies are needed to further elucidate the cumulative relationship between CaP risk alleles and CaP aggressiveness.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Case-Control Studies
  • Chromosomes, Human, Pair 17*
  • Chromosomes, Human, Pair 8*
  • Genetic Predisposition to Disease
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • ROC Curve
  • Risk Factors
  • Sensitivity and Specificity